mAbxience plant in Buenos Aires

presentation

History

Founded in 2008 by a team of scientists with over 25 years of experience in the development and production of biopharmaceuticals with expert knowledge of GMPs and regulatory pathways.

The facility was acquired by mAbxience in 2010.

Extensive experience in the development and production of interferon alfa, filgrastim, molgramostim, interleukin 2, erythropoietin, interferon beta and hepatitis B vaccine for both the national and export markets.

In 2012, it became the first facility in South America to produce mAbs using single-use technology.

It benefits from a young, multidisciplinary and international team, committed to the emerging field of biosimilars. Furthermore, mAbxience is supporting the training of local young people in the field of biotechnology.

 

Technology

The Buenos Aires facility is leading the way in the implementation of single-use technology in most of its processes, from preparation of the medium and cell cultivation to filtration.

The use of disposable bioreactors is one of the greatest innovations in the industry, which offers a dual advantage. Not only does it provide greater flexibility, enabling products to be changed in record time, it also completely eliminates the possibility of cross-contamination throughout this process.

Furthermore, using this technology significantly reduces the consumption of resources during the production processes. The use of water and cleaning agents is primarily reduced, by 80% and 90%, respectively, as the reactor no longer needs to be cleaned. This further limits the environmental impact of our facilities.